Elite Pharmaceuticals (OTCMKTS:ELTP) Issues Earnings Results

Elite Pharmaceuticals (OTCMKTS:ELTP) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, Zacks reports. Elite Pharmaceuticals had a return on equity of 37.06% and a net margin of 30.14%.

Elite Pharmaceuticals Stock Performance

Shares of OTCMKTS:ELTP traded down $0.00 on Thursday, hitting $0.36. The company’s stock had a trading volume of 913,100 shares, compared to its average volume of 617,123. The company has a market capitalization of $386.15 million, a price-to-earnings ratio of 17.93 and a beta of 0.40. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.22 and a current ratio of 6.45. Elite Pharmaceuticals has a 12 month low of $0.33 and a 12 month high of $0.74. The stock’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.38.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.